Atorvastatin
Treatment for Metabolic Syndrome
Typical Dosage: 10-80mg daily
Effectiveness
80%
Safety Score
65%
Clinical Trials
37
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
65
DangerousModerateSafe
Treatment Details
Dosage Range
10-80mg daily
Time to Effect
2-4 weeks for lipid lowering
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
35(Treat 35 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50
Monitoring:$200
Side Effect Mgmt:$75
Total Annual:$325
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$382
Atorvastatin Outcomes
for Metabolic Syndrome
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+85%
Common Side Effects
Muscle pain (myalgia)
+7%
Liver enzyme elevation
+2%
New-onset diabetes
+0.5%
Active Clinical Trials
1 active trial recruiting for Atorvastatin in Metabolic Syndrome
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
NCT05488067RECRUITINGPHASE4
10 participants
INTERVENTIONAL
Shanghai, China
Started: Mar 22, 2022
Completed Clinical Trials
15 completed trials for Atorvastatin in Metabolic Syndrome
Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin
NCT01785615COMPLETEDPHASE1, PHASE2
116 participants
INTERVENTIONAL
Rochester, United States
Started: Nov 1, 2004
ROMEO (Rosuvastatin in Metabolic syndrOme)
NCT00395486COMPLETEDPHASE4
258 participants
INTERVENTIONAL
Pusan, South Korea +2 more
Started: Sep 1, 2006
Implications for Treatment of the Metabolic Syndrome
NCT00666029COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Started: Feb 1, 2006
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
NCT00654485COMPLETEDPHASE3
940 participants
INTERVENTIONAL
Started: May 1, 2002
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
NCT00166036COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Atlanta, United States
Started: Sep 1, 2004
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
NCT02503865COMPLETEDPHASE1, PHASE2
351 participants
INTERVENTIONAL
Astana, Kazakhstan
Started: Jan 1, 2003
Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
NCT00409773COMPLETEDPHASE3
1.14K participants
INTERVENTIONAL
Started: Jan 1, 2007
The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women
NCT01072097COMPLETEDNA
30 participants
INTERVENTIONAL
Oulu, Finland
Started: Sep 1, 2006
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00632840COMPLETEDPHASE4
11 participants
INTERVENTIONAL
Started: Jun 1, 2001
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
NCT01448174COMPLETEDPHASE4
310 participants
INTERVENTIONAL
Nowy TomyΕl, Poland
Started: Oct 1, 2011
Atorvastatin Β± Aspirin in Lynch Syndrome Syndrome
NCT04379999COMPLETEDEARLY_PHASE1
43 participants
INTERVENTIONAL
Philadelphia, United States
Started: Sep 10, 2018
Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)
NCT00157924COMPLETEDPHASE4
190 participants
INTERVENTIONAL
Started: Nov 1, 2005
Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
NCT00665834COMPLETEDPHASE4
18 participants
INTERVENTIONAL
Kingston, Canada +1 more
Started: Apr 1, 2006
Caduet and TLC Intervention in Metabolic Syndrome
NCT03504735COMPLETEDPHASE4
53 participants
INTERVENTIONAL
Started: May 1, 2005
Change in Plaque Characteristics With Atorvastatin
NCT00700037COMPLETEDPHASE4
70 participants
INTERVENTIONAL
Wakayama, Japan
Started: Aug 1, 2009
Showing 20 of 37 total trials